Experiences with Diagnosis and Treatment of Chagas Disease at a United States Teaching Hospital—Clinical Features of Patients with Positive Screening Serologic Testing

• Main Authors: Peter Hyson, Lilian Vargas Barahona, Laura C. Pedraza-Arévalo, Jonathan Schultz, Luisa Mestroni, Maria da Consolação Moreira, Matthew Taylor, Carlos Franco-Paredes, Esther Benamu, Poornima Ramanan, Anis Rassi, Kellie Hawkins, Andrés F. Henao-Martínez
• Format: Article
• Language: English
• Published: MDPI AG 2021-05-01
• Series: Tropical Medicine and Infectious Disease
• Subjects: Chagas disease; trypanosomiasis; <i>Trypanosoma cruzi</i>; neglected tropical disease (NTD); pretransplant screening
• Online Access: https://www.mdpi.com/2414-6366/6/2/93

Chagas disease (CD) is the third most common parasitic infection globally and can cause cardiac and gastrointestinal complications. Around 300,000 carriers of CD live in the U.S., with about 3000 of those in Colorado. We described our experience in diagnosing CD at a Colorado teaching hospital to revise screening eligibility criteria. From 2006 to 2020, we reviewed <i>Trypanosoma cruzi</i> (TC) IgG serology results for 1156 patients in our institution. We identified 23 patients (1.99%) who had a positive test. A total of 14/23 (60%) of positive serologies never had confirmatory testing, and 7 of them were lost to follow up. Confirmatory testing, performed in 9 patients, resulted in being positive in 3. One additional case of CD was identified by positive tissue pathology. All four confirmed cases were among patients born in Latin America. While most of the testing for CD at our institution is part of the pretransplant screening, no confirmed cases of CD derived from this strategy. Exposure risk in this population is not always documented, and initial positive results from screening are not always confirmed. The lack of standardized screening protocols for CD in our institution contributes to underdiagnosis locally and in health systems nationwide. Given a large number of individuals in the U.S. with chronic CD, improved screening is warranted.